Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Women's Health Events

Women's health events Inicio
          For Consumers
          Women's Health
          OWH Education and Training
          Women's Health Events
          Menopause: Potential Impact on Clinical Pharmacology and Opportunities for Future Research - 10/11/2023Women's Health Events Workshop
    Event Title
              Menopause: Potential Impact on Clinical Pharmacology and Opportunities for Future Research


                  October 11, 2023

  Scheduled

    
  Share
    Post
    Linkedin

    Email
    PrintOn This Page
      Meeting Information
                Event Materials
                        ContactDate:
          
  


     
           

October 11, 2023   

 
 
        
                                      Time: 
                                      
10:00 AM
    - 2:00 PM
ET
                
  Organized By: 
      Organizer
          Office of Women's Health

 

  Image
              FDA Office of Women's Health Public Workshop Menopause: Potential Impact on Clinical Pharmacology and Opportunities for Future ResearchThe FDA Office of Women’s Health (OWH), in collaboration with the Center for Drug Evaluation and Research (CDER) Office of Clinical Pharmacology (OCP), will host a **free virtual public workshop** to discuss the current understanding of the impact of menopause on drug pharmacology and highlight the areas with the greatest need for further research and exploration. OWH works to protect, promote and advance the health of women through research, education, and outreach.

This workshop will include presentations and session discussions by experts in the fields of clinical pharmacology, obstetrics and gynecology, endocrinology, and clinical care. Each session will include a Q&A to respond to questions from attendees.

Speakers will discuss the current understanding of the impact of menopause on the pharmacokinetics (PK), pharmacodynamics (PD), and exposure-response relationships of FDA-regulated drugs and biologics used by menopausal women for non-menopause-related indications. The discussion is intended to identify the research and data gaps regarding the potential impact of menopause on PK/PD.

The workshop will be held virtually on the Zoom platform and registrants will receive a link to attend the workshop after completing their registration. Live closed captioning will be available during the workshop. If you require additional accommodations, please request them when completing your registration.

A video recording of this workshop will be available on the OWH website a few weeks after the workshop ends.

For questions about this event please email OWHmeetings@fda.hhs.gov.

View workshop recording here

**Meeting objectives**

Examine the biological and physiological changes that occur during menopause.
	Discuss the current understanding of the impact of menopause on the pharmacokinetics (PK), pharmacodynamics (PD), and exposure-response relationships of FDA-regulated products used by menopausal women for non-menopause-related indications.
	Discuss whether the changes in drug absorption, distribution, metabolism, and elimination, if any, are specifically due to hormonal changes of menopause (independent of age), or other non-hormonal influences (including age-related renal and hepatic changes).
	Identify the research and data gaps regarding the impact of menopause on PK/PD, highlighting areas with the greatest need for further research and exploration.Menopause: Potential Impact on Clinical Pharmacology and Opportunities for Future Research; Public Workshop (Federal Register Notice 9/21/23)

Agenda

10:00 a.m.
			**Opening remarks**

			Welcome and housekeeping remarks - **Susan Bersoff-Matcha, MD,**Deputy Director,****Office of Women’s Health (OWH), Food and Drug Administration10:03 a.m.
			OWH opening remarks - **Kaveeta Vasisht, MD, PharmD,**Associate Commissioner for Women’s Health and Director of the Office of Women’s Health, Food and Drug Administration10:05 a.m.
			Keynote – **Janet Woodcock, MD,** Principal Deputy Commissioner, Food and Drug Administration**Session I: Overview of biological changes of menopause**

			**Objectives:** Provide an overview of the biological and physiological changes that occur during the menopause transition and the resulting impact on health outcomes. Discuss perimenopause, surgical vs. natural menopause, and the impact of age, race, and ethnicity on menopause.

			**Moderator:** **Christina Chang, MD, MPH,** Division of Urology, Obstetrics, and Gynecology, Food and Drug Administration.10:10 a.m.
			**Nanette Santoro, MD,** Professor and E. Stewart Taylor Chair, Department of Obstetrics and Gynecology, University of Colorado School of Medicine10:30 a.m.
			**Gloria Richard-Davis, MD, MBA, NCMP, FACOG,** Reproductive Endocrinology Obstetrician/Gynecologist; Executive Director, Division for Diversity, Equity & Inclusion, Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences (UAMS)10:50 a.m.
			**Cynthia A. Stuenkel, MD,** Clinical Professor of Medicine, Endocrinology and Metabolism, University of California San Diego School of Medicine11:10 a.m.
			Q & A11:25 a.m.
			Break**Session II: Menopause and PK/PD**

			**Objectives:** The effects of menopause on the PK/PD of drugs are largely unknown. Sex hormone changes during menopause may affect the metabolic pathways of drugs by affecting drug metabolizing enzymes. Hormone changes may also affect other pathways that play an important role for drug disposition and excretion. In addition, many women experience weight gain at menopause. These changes have the potential to result in changes to drug PK. Furthermore, the physiological changes in menopause may result in altered sensitivity to drug response independent of changes in PK. This panel will discuss whether and how these variables could be considered during medical product development and the challenges and opportunities for addressing knowledge gaps.

			**Moderator: Rajanikanth (Raj) Madabushi, PhD**, Associate Director, Guidance and Scientific Policy, Office of Clinical Pharmacology, Food and Drug Administration11:35 a.m.
			**Leslie Z. Benet, PhD,** Professor and Former Chair, Department of Bioengineering & Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California San Francisco11:55 a.m.
			**Virginia Miller, MBA, PhD,**Professor Emerita, Surgery and Physiology, Mayo Clinic12:15 p.m.
			Break12:25 p.m.
			**Audrey Gassman, MD,** Deputy Director, Division of Urology, Obstetrics, and Gynecology, Food and Drug Administration12:45 p.m.
			**Yanhui Lu, PhD,**Office of Clinical Pharmacology, Food and Drug Administration1:05 p.m.
			Q & A1:25 p.m.
			Closing Remarks





Event Materials

  Title
            File Type/SizeWorkshop Speaker and Moderator Bios
              pdf               (850.67 KB)





      Contact
      Event Contact
          Office of Women's Health
				
					Food and Drug Administration
Office of Women's Health
10903 New Hampshire Ave WO32-2333
Silver Spring, MD 20993

(301) 796-9440 Phone
		
		
					owh@fda.gov

                                                                                  Content current as of:
      11/22/2023More Meetings,
      Conferences, and
      Workshops
        
        Women's health events
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop